Affiliation:
1. Gregory A. Petsko, a Fellow of the American Academy since 2002, is Professor of Neurology at Weill Cornell Medical College and Tauber Professor of Biochemistry and Chemistry Emeritus at Brandeis University. His research interests include enzyme structure and function and the development of treatments for Alzheimer's, Parkinson's, and Lou Gehrig's diseases. For the past twelve years he has written a column on science and society that first appears monthly in the journal Genome Biology. A compilation of...
Abstract
The Earth's population is aging fast, and the coming sharp increase in the number of people over age sixty-five will bring with it an epidemic of age-related neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Currently, no cures exist for the major neurologic disorders. Unless cures can be found, by 2050 the cost of these diseases will exceed $1 trillion annually in the United States, and the burden for other countries will scale with their populations. Despite exciting advances in our understanding of these diseases, both government research funding and the efforts of industry have failed to keep pace with this unmet medical need. Private philanthropy has done better, but the total dollars spent on developing diagnostics and therapeutics for neurologic disorders still lags far behind that spent on much less prevalent diseases. The challenge for biomedical research in the next forty years is to identify markers that would allow early detection of high-risk cohorts, and to develop therapies that either will prevent the diseases from starting at all in susceptible populations or will arrest their progression before severe damage to the central nervous system has occurred.
Subject
History and Philosophy of Science,Political Science and International Relations,Social Sciences (miscellaneous),Arts and Humanities (miscellaneous)
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献